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The Inhibitory Effects Demonstrated by Manuka Honey on Biofilms:  
How Manuka Honey May Soon Replace Conventional Antibiotic Therapy 
The surge of antibiotic-resistant bacteria has raised substantial concerns over how to 
effectively and efficiently control antibiotic-resistant bacteria capable of secreting 
biofilms. A biofilm can be defined as a self-producing extracellular matrix (Carter, et, 
al., 2016). Manuka honey, an alternative to conventional antibiotics, has proven 
successful in inhibiting planktonic cells and killing bacteria living under the protection 
of biofilms (Brudzynski & Sjaarda, 2015). 
The Origins of Manuka Honey 
Manuka honey is produced by selective Leptospermum species native to New Zealand 
and Australia, and is colonized by the honey bees, Apis mellifera (Brudzynski & 
Sjaarda, 2015). Levels of antimicrobial components contained in different batches of 
Manuka honey can range from 100ppm to greater than 1200ppm (Carter, et, al., 2016). 
Therefore, antibacterial activity of Manuka honey has to be tested individually. 
Medical-grade Manuka honey is subjected to gamma radiation in order to ensure its 
sterility (Carter, et. al., 2016). The medical community developed the phenol-equivalent 
scale as a standard to express the potency of antibacterial activity. 
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Introduction 
Anti-Biofilm Activity in Manuka Honey  
in Combination with Antibiotics 
Further Applications 
References 
Gastrointestinal Ulcers 
Almasaudi et. al. (2016) has performed experiments to assess gastroprotective effects 
associated with Manuka honey against ethanol-induced gastric ulcers in rats. After 
experimentation, the researchers were able to conclude that Manuka honey 
substantially lowered the rats’ ulcer index, indicating that it protected the gastric 
mucosa from lesions and preserved gastric mucosal glycoproteins. Further research and 
experimentation is still needed in order to determine if Manuka honey is able to 
produce similar anti-ulcer outcomes in humans.  
  
Anti-Cancerous Properties 
Vallianou, Evangelopoulos, Skourtis, and Kazazi (2017) have confirmed with in-vitro 
experimentation, the anti-cancerous properties of Manuka honey via apoptosis. 
Scientists believe that Manuka honey induces caspase-9, which in turn, activates the 
caspase-3 executor proteins. These caspase enzymes are directly involved in the death 
receptor signaling pathway, which ultimately induces apoptosis (Vallianou, et. al., 
2017). This contributes to the immune-protective and immune-modulatory activity, 
which is closely associated with anti-cancerous properties. In vivo testing has yet to be 
conducted. Therefore, Manuka honey’s interaction in the human body is unknown and 
may inhibit or alter some of the anti-cancerous properties observed. 
Manuka honey has been proven to inhibit in-vitro antibiofilm experiments. More specifically, 
Gentamicin and Manuka honey produced an additive interaction against P. aeruginosa biofilms 
and a synergistic interaction with vancomycin against S. aureus biofilms (Campeau & Patel, 
2014). When Manuka honey dressings were utilized in conjunction with oxacillin, tetracycline, 
imipenem, and mupirocim; a synergistic effect was achieved against MRSA (Carter, et, al., 
2016). The findings suggested that the combined therapeutic intervention of Manuka honey 
wound dressings and antimicrobials could lower the dosage of antimicrobial medications 
required to inhibit the biofilm as well as prevent the development of resistance.  
  
Manuka honey’s bactericidal action is associated with non-peroxide antibacterial activity 
(NPABA). In-vitro isolates with multi-drug resistant phenotypes have not demonstrated any 
reduction in their susceptibility nor generated any honey-resistant strains to Manuka honey 
when administered at inhibitory levels under normal laboratory conditions (Carter, et, al., 
2016). While bactericidal effects were seen in both planktonic cultures and biofilms, a higher 
concentration of Manuka honey was required to inhibit sessile bacteria, compared to its 
counterpart, free-living bacteria (Hammond, et. al., 2014). Test strains of well-known 
pathogenic bacteria were inhibited at lower concentrations in a liquid medium compared to on 
agar well diffusion plates (Hammond, et. al., 2014). This finding may be attributed to the 
ability of the components of Manuka honey to diffuse more readily and uniformly in a liquid 
medium due to the osmotic effects. 
Anti-Microbial Properties of Manuka Honey 
Methylglyoxal: Unique Manuka Factor (UMF) 
In foods and others honeys, methylglyoxal levels are usually between 3-37mg/kg and no 
greater than 24mg/kg respectively, whereas levels of methylglyoxal in Manuka honey have 
been recorded as high as 1541 mg/kg (Kwakman, & Zaat, 2012). Methylglyoxal successfully 
kills bacteria at submicromolar concentrations by a slow mechanism of action, explaining the 
potent but slow bacterial activity of Manuka honey. However, when just methylglyoxal was 
introduced to P. aeruginosa and E. coli samples, it did not prove to be completely inhibitory, 
suggesting other components may be partially responsible for antibacterial activity (Kwakman 
& Zaat, 2012). 
  
Osmotic Stress, Leptosin, and Phenolic Components 
Carter, et. al. (2016) successfully demonstrated that the combination of a high sugar content 
and low pH, which promotes osmotic stress, inhibits microbial growth, even when the honey 
has been diluted to 30-40% (Kwakman & Zaat, 2012). Methyl syringate 4-O--D gentiobiose, 
commonly referred to as Leptosin, a glycoside found exclusively in Leptospermum, was found 
to have a positive correlation with the UMF value. This may indicate that levels of leptosin 
may be linked to the modulation of antimicrobial activity (Carter, et, al., 2016). Marcucci 
(1995) concluded in an experiment that phenolic acids including flavonoids derived from 
propolis and present in Manuka honey, exhibited weak antibacterial activity, have potentially 
contributing to the observed non-peroxide antibacterial activity (NPABA). 
  
Isolation of a 5.8-kDa Component  
Tonks, et. al. (2007) discovered a 5.8 kDa component in Manuka honey that stimulates human 
immune cells via TLR4, or the cytokine induction in human monocytes. This component was 
determined to be directly involved in the mechanism which stimulates innate immune cells to 
respond. While it is unknown whether this moiety is unique to Manuka honey or universally 
present in all honeys, it does appear to play a role in the antimicrobial activity observed in 
Manuka honey (Tonks, et. al., 2007).  
Biofilms Susceptible to Manuka Honey  
Formation of Biofilms 
Methicillin-Resistant Staphyloccocus aureus (MRSA) 
Jenkins and colleagues (2011) examined how Manuka honey successfully inhibits 
biofilm formation in MRSA and determined that Manuka honey was able to interrupt 
the cell cycle during the cytokinesis stage. Further, the research team noted a spike in 
the numbers of fully formed septa in MRSA, indicating that the bacteria was unable 
to successfully separate following the formation of cross walls (Jenkins, et. al., 2011). 
Henriques et. al. (2009) also confirmed this finding by detecting an increase in 
sensitivity of autolysin mutant, UspA, which is associated with bacterial cell division, 
and an essential component required for MRSA to exhibit full pathogenicity.  
  
Clostridium difficile (C. diff) 
With C. difficile contributing to 30-50% of all nosocomial infections, it is 
pertinent to determine and implement effective treatment methods in order to combat 
this species of bacteria (Giles, & Labeij, 2017). Currently, fecal microbiota 
transplantation (FMT) is the most widely accepted and implemented treatment 
method. Giles and Labeij (2017) cite the use of commercially available Manuka 
honey with UMF 26+ with a patient with persistent C. difficile infection. After 
treatment with two honey lavages a week apart, a sample removed from the patient’s 
colon did not detect C. difficile (Giles, & Labeij, 2017). This discovery provides a 
promising alternative for the treatment of C. difficile infections. 
  
When the structures and functions of various biofilms were assessed, their mechanisms 
of resistance appeared to be dependent upon multicellular strategies. First, the higher the 
number of cells present in a given area increases the resistance of these cells to 
conventional antibiotics (Lin, et. al., 2010) In addition, biofilms contain persister cells, 
requiring minimal amounts of energy in order to survive for long durations (Cundell & 
Wilkinson, n.d.). Therefore, as the surface level cells die, they offer a protective layer of 
impenetrability for persister cells in the center of the biofilm (Cundell & Wilkinson, 
n.d.). Finally, in order for biofilms to be present, an initial adherence to a physical 
material is required. (Lin, et. al., 2010).  
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